Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

Next Previous
Trial Profile

A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use
  • Acronyms AURORA
  • Sponsors Amgen; ChemoCentryx

Most Recent Events

  • 21 Mar 2023 Results assessing Plasma biomarkers for clinical response and disease severity identified from Hidradenitis Suppurativa patients presented at the American Academy of Dermatology annual Meeting 2023
  • 24 Feb 2022 Status changed from active, no longer recruiting to completed.
  • 28 Oct 2020 Primary endpoint has not been met. (Proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.), according to a ChemoCentryx media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top